The rapid success of SGLT2 inhibitors reflects not only their strong mechanistic rationale but also broad applicability across HF phenotypes and the advantage of testing within large cardiovascular outcome trials originally designed for diabetes. Here, SLC5A2 is linked to hydrops fetalis.